Skip to main content
Erschienen in: Heart Failure Reviews 6/2017

19.07.2017

The MOGE(S) classification for cardiomyopathies: current status and future outlook

verfasst von: Julian G. Westphal, Angelos G. Rigopoulos, Constantinos Bakogiannis, Sarah E. Ludwig, Sophie Mavrogeni, Boris Bigalke, Torsten Doenst, Matthias Pauschinger, Carsten Tschöpe, P. Christian Schulze, Michel Noutsias

Erschienen in: Heart Failure Reviews | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Cardiomyopathies are complex diseases of multifactorial pathogenesis and have a high morbidity and mortality. Over the past decades, several revisions of classifications and definitions of cardiomyopathies have been proposed, primarily focusing on the phenotypic characterization of cardiomyopathies. The MOGE(S) classification system published in 2013 encompasses the classification of rapidly growing knowledge on genetic mutations, acquired causes (i.e., intramyocardial inflammation, viral infections), and further conditions involved in the induction of cardiomyopathies (e.g., storage diseases, toxicity). It is based on five attributes, including morphofunctional characteristics (M), organ involvement (O), genetic or familial inheritance pattern (G), etiological annotation (E), and optional information about the heart failure functional status (S). This review summarizes the development, the cornerstones of the MOGE(S) classification, and the published data on the clinical relevance of the MOGE(S) classification. We furthermore discuss new issues which might be considered for future updates of the MOGE(S) classification of cardiomyopathies.
Literatur
1.
Zurück zum Zitat (1980) Report of the WHO/ISFC task force on the definition and classification of cardiomyopathies Br Heart J 44(6):672–673 (1980) Report of the WHO/ISFC task force on the definition and classification of cardiomyopathies Br Heart J 44(6):672–673
2.
Zurück zum Zitat Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O’Connell J, Olsen E, Thiene G, Goodwin J, Gyarfas I, Martin I, Nordet P (1996) Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 93(5):841–842CrossRefPubMed Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O’Connell J, Olsen E, Thiene G, Goodwin J, Gyarfas I, Martin I, Nordet P (1996) Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 93(5):841–842CrossRefPubMed
3.
Zurück zum Zitat Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, Varnava A, Mahon NG, McKenna WJ (2000) Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 36(7):2212–2218CrossRefPubMed Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, Varnava A, Mahon NG, McKenna WJ (2000) Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 36(7):2212–2218CrossRefPubMed
4.
Zurück zum Zitat Olbrich HG (2001) Epidemiology-etiology of dilated cardiomyopathy. Zeitschrift fur Kardiologie 90(Suppl 1):2–9CrossRefPubMed Olbrich HG (2001) Epidemiology-etiology of dilated cardiomyopathy. Zeitschrift fur Kardiologie 90(Suppl 1):2–9CrossRefPubMed
6.
Zurück zum Zitat Brigden W (1957) Uncommon myocardial diseases; the non-coronary cardiomyopathies. Lancet 273(7007):1179–1184CrossRefPubMed Brigden W (1957) Uncommon myocardial diseases; the non-coronary cardiomyopathies. Lancet 273(7007):1179–1184CrossRefPubMed
8.
Zurück zum Zitat Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB (2006) Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 113(14):1807–1816CrossRefPubMed Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB (2006) Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 113(14):1807–1816CrossRefPubMed
9.
Zurück zum Zitat Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, Dubourg O, Kühl U, Maisch B, McKenna WJ, Monserrat L, Pankuweit S, Rapezzi C, Seferovic P, Tavazzi L, Keren A (2008) Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 29(2):270–276CrossRefPubMed Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, Dubourg O, Kühl U, Maisch B, McKenna WJ, Monserrat L, Pankuweit S, Rapezzi C, Seferovic P, Tavazzi L, Keren A (2008) Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 29(2):270–276CrossRefPubMed
11.
Zurück zum Zitat Arbustini E, Narula N, Dec GW, Reddy KS, Greenberg B, Kushwaha S, Marwick T, Pinney S, Bellazzi R, Favalli V, Kramer C, Roberts R, Zoghbi WA, Bonow R, Tavazzi L, Fuster V, Narula J (2013) The MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy: endorsed by the World Heart Federation. J Am Coll Cardiol 62(22):2046–2072. doi:10.1016/j.jacc.2013.08.1644 CrossRefPubMed Arbustini E, Narula N, Dec GW, Reddy KS, Greenberg B, Kushwaha S, Marwick T, Pinney S, Bellazzi R, Favalli V, Kramer C, Roberts R, Zoghbi WA, Bonow R, Tavazzi L, Fuster V, Narula J (2013) The MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy: endorsed by the World Heart Federation. J Am Coll Cardiol 62(22):2046–2072. doi:10.​1016/​j.​jacc.​2013.​08.​1644 CrossRefPubMed
12.
Zurück zum Zitat Vaikhanskaya T, Sivitskaya L, Danilenko N, Davydenko O, Kurushka T, Sidorenko I (2014) LMNA-related dilated cardiomyopathy. Oxf Med Case Rep 2014(6):102–104. doi:10.1093/omcr/omu040 CrossRef Vaikhanskaya T, Sivitskaya L, Danilenko N, Davydenko O, Kurushka T, Sidorenko I (2014) LMNA-related dilated cardiomyopathy. Oxf Med Case Rep 2014(6):102–104. doi:10.​1093/​omcr/​omu040 CrossRef
14.
15.
Zurück zum Zitat Arbustini E, Narula N, Dec GW, Reddy KS, Greenberg B, Kushwaha S, Marwick T, Pinney S, Bellazzi R, Favalli V, Kramer C, Roberts R, Zoghbi WA, Bonow R, Tavazzi L, Fuster V, Narula J (2014) Reply: the MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy: more questions than answers? J Am Coll Cardiol 63(23):2584–2586. doi:10.1016/j.jacc.2014.03.028 CrossRefPubMed Arbustini E, Narula N, Dec GW, Reddy KS, Greenberg B, Kushwaha S, Marwick T, Pinney S, Bellazzi R, Favalli V, Kramer C, Roberts R, Zoghbi WA, Bonow R, Tavazzi L, Fuster V, Narula J (2014) Reply: the MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy: more questions than answers? J Am Coll Cardiol 63(23):2584–2586. doi:10.​1016/​j.​jacc.​2014.​03.​028 CrossRefPubMed
16.
Zurück zum Zitat Hazebroek MR, Moors S, Dennert R, van den Wijngaard A, Krapels I, Hoos M, Verdonschot J, Merken JJ, de Vries B, Wolffs PF, Crijns HJ, Brunner-La Rocca HP, Heymans S (2015) Prognostic relevance of gene-environment interactions in patients with dilated cardiomyopathy: applying the MOGE(S) classification. J Am Coll Cardiol 66(12):1313–1323. doi:10.1016/j.jacc.2015.07.023 CrossRefPubMed Hazebroek MR, Moors S, Dennert R, van den Wijngaard A, Krapels I, Hoos M, Verdonschot J, Merken JJ, de Vries B, Wolffs PF, Crijns HJ, Brunner-La Rocca HP, Heymans S (2015) Prognostic relevance of gene-environment interactions in patients with dilated cardiomyopathy: applying the MOGE(S) classification. J Am Coll Cardiol 66(12):1313–1323. doi:10.​1016/​j.​jacc.​2015.​07.​023 CrossRefPubMed
17.
Zurück zum Zitat Agarwal A, Yousefzai R, Jan MF, Cho C, Shetabi K, Bush M, Khandheria BK, Paterick TE, Treiber S, Sra J, Werner P, Allaqaband S, Bajwa T, Tajik AJ (2015) Clinical application of WHF-MOGE(S) classification for hypertrophic cardiomyopathy. Glob Heart 10(3):209–219. doi:10.1016/j.gheart.2015.01.001 CrossRefPubMed Agarwal A, Yousefzai R, Jan MF, Cho C, Shetabi K, Bush M, Khandheria BK, Paterick TE, Treiber S, Sra J, Werner P, Allaqaband S, Bajwa T, Tajik AJ (2015) Clinical application of WHF-MOGE(S) classification for hypertrophic cardiomyopathy. Glob Heart 10(3):209–219. doi:10.​1016/​j.​gheart.​2015.​01.​001 CrossRefPubMed
18.
Zurück zum Zitat Cheitlin MD, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, Davis JL, Douglas PS, Faxon DP, Gillam LD, Kimball TR, Kussmaul WG, Pearlman AS, Philbrick JT, Rakowski H, Thys DM, Antman EM, Smith SC Jr, Alpert JS, Gregoratos G, Anderson JL, Hiratzka LF, Hunt SA, Fuster V, Jacobs AK, Gibbons RJ, Russell RO, American College of C, American Heart A, American Society of E (2003) ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation 108(9):1146–1162. doi:10.1161/01.CIR.0000073597.57414.A9 CrossRefPubMed Cheitlin MD, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, Davis JL, Douglas PS, Faxon DP, Gillam LD, Kimball TR, Kussmaul WG, Pearlman AS, Philbrick JT, Rakowski H, Thys DM, Antman EM, Smith SC Jr, Alpert JS, Gregoratos G, Anderson JL, Hiratzka LF, Hunt SA, Fuster V, Jacobs AK, Gibbons RJ, Russell RO, American College of C, American Heart A, American Society of E (2003) ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation 108(9):1146–1162. doi:10.​1161/​01.​CIR.​0000073597.​57414.​A9 CrossRefPubMed
19.
Zurück zum Zitat Habib G, Bucciarelli-Ducci C, Caforio ALP, Cardim N, Charron P, Cosyns B, Dehaene A, Derumeaux G, Donal E, Dweck MR, Edvardsen T, Erba PA, Ernande L, Gaemperli O, Galderisi M, Grapsa J, Jacquier A, Klingel K, Lancellotti P, Neglia D, Pepe A, Perrone-Filardi P, Petersen SE, Plein S, Popescu BA, Reant P, Sade LE, Salaun E, Slart R, Tribouilloy C, Zamorano J, Reviewers: Victoria Delgado KH, Vijayaraghavan G (2017) Multimodality imaging in restrictive cardiomyopathies: an EACVI expert consensus document: In collaboration with the ‘Working Group on myocardial and pericardial diseases’ of the European Society of Cardiology Endorsed by the Indian Academy of Echocardiography. Eur Heart J Cardiovasc Imaging. doi:10.1093/ehjci/jex034 Habib G, Bucciarelli-Ducci C, Caforio ALP, Cardim N, Charron P, Cosyns B, Dehaene A, Derumeaux G, Donal E, Dweck MR, Edvardsen T, Erba PA, Ernande L, Gaemperli O, Galderisi M, Grapsa J, Jacquier A, Klingel K, Lancellotti P, Neglia D, Pepe A, Perrone-Filardi P, Petersen SE, Plein S, Popescu BA, Reant P, Sade LE, Salaun E, Slart R, Tribouilloy C, Zamorano J, Reviewers: Victoria Delgado KH, Vijayaraghavan G (2017) Multimodality imaging in restrictive cardiomyopathies: an EACVI expert consensus document: In collaboration with the ‘Working Group on myocardial and pericardial diseases’ of the European Society of Cardiology Endorsed by the Indian Academy of Echocardiography. Eur Heart J Cardiovasc Imaging. doi:10.​1093/​ehjci/​jex034
20.
21.
Zurück zum Zitat Grun S, Schumm J, Greulich S, Wagner A, Schneider S, Bruder O, Kispert EM, Hill S, Ong P, Klingel K, Kandolf R, Sechtem U, Mahrholdt H (2012) Long-term follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery. J Am Coll Cardiol 59(18):1604–1615. doi:10.1016/j.jacc.2012.01.007 CrossRefPubMed Grun S, Schumm J, Greulich S, Wagner A, Schneider S, Bruder O, Kispert EM, Hill S, Ong P, Klingel K, Kandolf R, Sechtem U, Mahrholdt H (2012) Long-term follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery. J Am Coll Cardiol 59(18):1604–1615. doi:10.​1016/​j.​jacc.​2012.​01.​007 CrossRefPubMed
22.
Zurück zum Zitat Lehrke S, Lossnitzer D, Schob M, Steen H, Merten C, Kemmling H, Pribe R, Ehlermann P, Zugck C, Korosoglou G, Giannitsis E, Katus HA (2011) Use of cardiovascular magnetic resonance for risk stratification in chronic heart failure: prognostic value of late gadolinium enhancement in patients with non-ischaemic dilated cardiomyopathy. Heart 97(9):727–732. doi:10.1136/hrt.2010.205542 CrossRefPubMed Lehrke S, Lossnitzer D, Schob M, Steen H, Merten C, Kemmling H, Pribe R, Ehlermann P, Zugck C, Korosoglou G, Giannitsis E, Katus HA (2011) Use of cardiovascular magnetic resonance for risk stratification in chronic heart failure: prognostic value of late gadolinium enhancement in patients with non-ischaemic dilated cardiomyopathy. Heart 97(9):727–732. doi:10.​1136/​hrt.​2010.​205542 CrossRefPubMed
23.
Zurück zum Zitat Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert EM, Nassenstein K, Schlosser T, Sabin GV, Sechtem U, Mahrholdt H (2010) Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 56(11):875–887CrossRefPubMed Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert EM, Nassenstein K, Schlosser T, Sabin GV, Sechtem U, Mahrholdt H (2010) Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 56(11):875–887CrossRefPubMed
24.
Zurück zum Zitat Greulich S, Kindermann I, Schumm J, Perne A, Birkmeier S, Grun S, Ong P, Schaufele T, Klingel K, Schneider S, Kandolf R, Bohm M, Sechtem U, Mahrholdt H (2016) Predictors of outcome in patients with parvovirus B19 positive endomyocardial biopsy. Clin Res Cardiol 105(1):37–52. doi:10.1007/s00392-015-0884-6 CrossRefPubMed Greulich S, Kindermann I, Schumm J, Perne A, Birkmeier S, Grun S, Ong P, Schaufele T, Klingel K, Schneider S, Kandolf R, Bohm M, Sechtem U, Mahrholdt H (2016) Predictors of outcome in patients with parvovirus B19 positive endomyocardial biopsy. Clin Res Cardiol 105(1):37–52. doi:10.​1007/​s00392-015-0884-6 CrossRefPubMed
27.
Zurück zum Zitat Grogan M, Redfield MM, Bailey KR, Reeder GS, Gersh BJ, Edwards WD, Rodeheffer RJ (1995) Long-term outcome of patients with biopsy-proved myocarditis: comparison with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 26(1):80–84CrossRefPubMed Grogan M, Redfield MM, Bailey KR, Reeder GS, Gersh BJ, Edwards WD, Rodeheffer RJ (1995) Long-term outcome of patients with biopsy-proved myocarditis: comparison with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 26(1):80–84CrossRefPubMed
28.
Zurück zum Zitat Mason JW, O’Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, Moon TE (1995) A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 333(5):269–275CrossRefPubMed Mason JW, O’Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, Moon TE (1995) A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 333(5):269–275CrossRefPubMed
29.
Zurück zum Zitat Kindermann I, Kindermann M, Kandolf R, Klingel K, Bultmann B, Muller T, Lindinger A, Bohm M (2008) Predictors of outcome in patients with suspected myocarditis. Circulation 118(6):639–648CrossRefPubMed Kindermann I, Kindermann M, Kandolf R, Klingel K, Bultmann B, Muller T, Lindinger A, Bohm M (2008) Predictors of outcome in patients with suspected myocarditis. Circulation 118(6):639–648CrossRefPubMed
30.
Zurück zum Zitat Cooper LT Jr, Berry GJ, Shabetai R (1997) Idiopathic giant-cell myocarditis—natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. N Engl J Med 336(26):1860–1866CrossRefPubMed Cooper LT Jr, Berry GJ, Shabetai R (1997) Idiopathic giant-cell myocarditis—natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. N Engl J Med 336(26):1860–1866CrossRefPubMed
31.
Zurück zum Zitat Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kühl U, Levine GN, Narula J, Starling RC, Towbin J, Virmani R (2007) The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation 116(19):2216–2233CrossRefPubMed Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kühl U, Levine GN, Narula J, Starling RC, Towbin J, Virmani R (2007) The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation 116(19):2216–2233CrossRefPubMed
32.
Zurück zum Zitat Ekstrom K, Lehtonen J, Kandolin R, Raisanen-Sokolowski A, Salmenkivi K, Kupari M (2016) Long-term outcome and its predictors in giant cell myocarditis. Eur J Heart Fail 18(12):1452–1458. doi:10.1002/ejhf.606 CrossRefPubMed Ekstrom K, Lehtonen J, Kandolin R, Raisanen-Sokolowski A, Salmenkivi K, Kupari M (2016) Long-term outcome and its predictors in giant cell myocarditis. Eur J Heart Fail 18(12):1452–1458. doi:10.​1002/​ejhf.​606 CrossRefPubMed
34.
Zurück zum Zitat Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, Glanowska G, Wilczewski P, Niklewski T, Zembala M, Polonski L, Rozek MM, Wodniecki J (2001) Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation 104(1):39–45CrossRefPubMed Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, Glanowska G, Wilczewski P, Niklewski T, Zembala M, Polonski L, Rozek MM, Wodniecki J (2001) Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation 104(1):39–45CrossRefPubMed
35.
Zurück zum Zitat Frustaci A, Russo MA, Chimenti C (2009) Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J 30(16):1995–2002CrossRefPubMed Frustaci A, Russo MA, Chimenti C (2009) Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J 30(16):1995–2002CrossRefPubMed
36.
37.
Zurück zum Zitat Noutsias M, Seeberg B, Schultheiss HP, Kühl U (1999) Expression of cell adhesion molecules in dilated cardiomyopathy: evidence for endothelial activation in inflammatory cardiomyopathy. Circulation 99(16):2124–2131CrossRefPubMed Noutsias M, Seeberg B, Schultheiss HP, Kühl U (1999) Expression of cell adhesion molecules in dilated cardiomyopathy: evidence for endothelial activation in inflammatory cardiomyopathy. Circulation 99(16):2124–2131CrossRefPubMed
38.
Zurück zum Zitat Noutsias M, Pauschinger M, Ostermann K, Escher F, Blohm JH, Schultheiss H, Kühl U (2002) Digital image analysis system for the quantification of infiltrates and cell adhesion molecules in inflammatory cardiomyopathy. Med Sci Monit 8(5):MT59–MT71PubMed Noutsias M, Pauschinger M, Ostermann K, Escher F, Blohm JH, Schultheiss H, Kühl U (2002) Digital image analysis system for the quantification of infiltrates and cell adhesion molecules in inflammatory cardiomyopathy. Med Sci Monit 8(5):MT59–MT71PubMed
39.
Zurück zum Zitat Noutsias M, Hohmann C, Pauschinger M, Schwimmbeck PL, Ostermann K, Rode U, Yacoub MH, Kühl U, Schultheiss HP (2003) sICAM-1 correlates with myocardial ICAM-1 expression in dilated cardiomyopathy. Int J Cardiol 91(2–3):153–161CrossRefPubMed Noutsias M, Hohmann C, Pauschinger M, Schwimmbeck PL, Ostermann K, Rode U, Yacoub MH, Kühl U, Schultheiss HP (2003) sICAM-1 correlates with myocardial ICAM-1 expression in dilated cardiomyopathy. Int J Cardiol 91(2–3):153–161CrossRefPubMed
41.
Zurück zum Zitat Fujioka S, Kitaura Y, Ukimura A, Deguchi H, Kawamura K, Isomura T, Suma H, Shimizu A (2000) Evaluation of viral infection in the myocardium of patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 36(6):1920–1926CrossRefPubMed Fujioka S, Kitaura Y, Ukimura A, Deguchi H, Kawamura K, Isomura T, Suma H, Shimizu A (2000) Evaluation of viral infection in the myocardium of patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 36(6):1920–1926CrossRefPubMed
42.
Zurück zum Zitat Norja P, Hokynar K, Aaltonen LM, Chen R, Ranki A, Partio EK, Kiviluoto O, Davidkin I, Leivo T, Eis-Hubinger AM, Schneider B, Fischer HP, Tolba R, Vapalahti O, Vaheri A, Soderlund-Venermo M, Hedman K (2006) Bioportfolio: lifelong persistence of variant and prototypic erythrovirus DNA genomes in human tissue. Proc Natl Acad Sci U S A 103(19):7450–7453CrossRefPubMedPubMedCentral Norja P, Hokynar K, Aaltonen LM, Chen R, Ranki A, Partio EK, Kiviluoto O, Davidkin I, Leivo T, Eis-Hubinger AM, Schneider B, Fischer HP, Tolba R, Vapalahti O, Vaheri A, Soderlund-Venermo M, Hedman K (2006) Bioportfolio: lifelong persistence of variant and prototypic erythrovirus DNA genomes in human tissue. Proc Natl Acad Sci U S A 103(19):7450–7453CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Verdonschot J, Hazebroek M, Merken J, Debing Y, Dennert R, Brunner-La Rocca HP, Heymans S (2016) Relevance of cardiac parvovirus B19 in myocarditis and dilated cardiomyopathy: review of the literature. Eur J Heart Fail 18(12):1430–1441. doi:10.1002/ejhf.665 CrossRefPubMed Verdonschot J, Hazebroek M, Merken J, Debing Y, Dennert R, Brunner-La Rocca HP, Heymans S (2016) Relevance of cardiac parvovirus B19 in myocarditis and dilated cardiomyopathy: review of the literature. Eur J Heart Fail 18(12):1430–1441. doi:10.​1002/​ejhf.​665 CrossRefPubMed
45.
Zurück zum Zitat Zimmermann O, Rodewald C, Radermacher M, Vetter M, Wiehe JM, Bienek-Ziolkowski M, Hombach V, Torzewski J (2010) Interferon beta-1b therapy in chronic viral dilated cardiomyopathy—is there a role for specific therapy? J Card Fail 16(4):348–356CrossRefPubMed Zimmermann O, Rodewald C, Radermacher M, Vetter M, Wiehe JM, Bienek-Ziolkowski M, Hombach V, Torzewski J (2010) Interferon beta-1b therapy in chronic viral dilated cardiomyopathy—is there a role for specific therapy? J Card Fail 16(4):348–356CrossRefPubMed
46.
Zurück zum Zitat Noutsias M (2016) Myocarditis. In: Maisel AS, Filippatos G (eds) Algorithms in heart failure, vol 1. Jaypee Brothers Medical Publishers (P) Ltd, New Delhi, pp 323–345 Noutsias M (2016) Myocarditis. In: Maisel AS, Filippatos G (eds) Algorithms in heart failure, vol 1. Jaypee Brothers Medical Publishers (P) Ltd, New Delhi, pp 323–345
47.
Zurück zum Zitat Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Authors/Task Force M (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37(27):2129–2200. doi:10.1093/eurheartj/ehw128 CrossRefPubMed Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Authors/Task Force M (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37(27):2129–2200. doi:10.​1093/​eurheartj/​ehw128 CrossRefPubMed
48.
Zurück zum Zitat Kasner M, Aleksandrov A, Escher F, Al-Saadi N, Makowski M, Spillmann F, Genger M, Schultheiss HP, Kuhl U, Pieske B, Morris DA, Noutsias M, Tschope C (2017) Multimodality imaging approach in the diagnosis of chronic myocarditis with preserved left ventricular ejection fraction (MCpEF): the role of 2D speckle-tracking echocardiography. Int J Cardiol. doi:10.1016/j.ijcard.2017.05.038 Kasner M, Aleksandrov A, Escher F, Al-Saadi N, Makowski M, Spillmann F, Genger M, Schultheiss HP, Kuhl U, Pieske B, Morris DA, Noutsias M, Tschope C (2017) Multimodality imaging approach in the diagnosis of chronic myocarditis with preserved left ventricular ejection fraction (MCpEF): the role of 2D speckle-tracking echocardiography. Int J Cardiol. doi:10.​1016/​j.​ijcard.​2017.​05.​038
49.
Zurück zum Zitat Noutsias M, Pauschinger M, Gross U, Lassner D, Schultheiss HP, Kuhl U (2008) Giant-cell myocarditis in a patient presenting with dilated cardiomyopathy and ventricular tachycardias treated by immunosuppression: a case report. Int J Cardiol 128(2):e58–e59CrossRefPubMed Noutsias M, Pauschinger M, Gross U, Lassner D, Schultheiss HP, Kuhl U (2008) Giant-cell myocarditis in a patient presenting with dilated cardiomyopathy and ventricular tachycardias treated by immunosuppression: a case report. Int J Cardiol 128(2):e58–e59CrossRefPubMed
50.
Zurück zum Zitat Kühl U, Pauschinger M, Schwimmbeck PL, Seeberg B, Lober C, Noutsias M, Poller W, Schultheiss HP (2003) Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 107(22):2793–2798CrossRefPubMed Kühl U, Pauschinger M, Schwimmbeck PL, Seeberg B, Lober C, Noutsias M, Poller W, Schultheiss HP (2003) Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 107(22):2793–2798CrossRefPubMed
52.
Zurück zum Zitat Arbustini E, Narula N, Dec GW, Reddy KS, Greenberg B, Kushwaha S, Marwick T, Pinney S, Bellazzi R, Favalli V, Kramer C, Roberts R, Zoghbi WA, Bonow R, Tavazzi L, Fuster V, Narula J (2014) MOGE(S) nosology in low-to-middle-income countries. Nat Rev Cardiol 11(5):307. doi:10.1038/nrcardio.2013.219-c1 CrossRefPubMed Arbustini E, Narula N, Dec GW, Reddy KS, Greenberg B, Kushwaha S, Marwick T, Pinney S, Bellazzi R, Favalli V, Kramer C, Roberts R, Zoghbi WA, Bonow R, Tavazzi L, Fuster V, Narula J (2014) MOGE(S) nosology in low-to-middle-income countries. Nat Rev Cardiol 11(5):307. doi:10.​1038/​nrcardio.​2013.​219-c1 CrossRefPubMed
54.
Zurück zum Zitat Kühl U, Lassner D, Pauschinger M, Gross UM, Seeberg B, Noutsias M, Poller W, Schultheiss HP (2008) Prevalence of erythrovirus genotypes in the myocardium of patients with dilated cardiomyopathy. J Med Virol 80(7):1243–1251CrossRefPubMed Kühl U, Lassner D, Pauschinger M, Gross UM, Seeberg B, Noutsias M, Poller W, Schultheiss HP (2008) Prevalence of erythrovirus genotypes in the myocardium of patients with dilated cardiomyopathy. J Med Virol 80(7):1243–1251CrossRefPubMed
55.
Zurück zum Zitat Lindner J, Noutsias M, Lassner D, Wenzel J, Schultheiss HP, Kuehl U, Modrow S (2009) Adaptive immune responses against parvovirus B19 in patients with myocardial disease. J Clin Virol 44(1):27–32CrossRefPubMed Lindner J, Noutsias M, Lassner D, Wenzel J, Schultheiss HP, Kuehl U, Modrow S (2009) Adaptive immune responses against parvovirus B19 in patients with myocardial disease. J Clin Virol 44(1):27–32CrossRefPubMed
56.
Zurück zum Zitat Escher F, Modrow S, Sabi T, Kuhl U, Lassner D, Schultheiss HP, Noutsias M (2008) Parvovirus B19 profiles in patients presenting with acute myocarditis and chronic dilated cardiomyopathy. Med Sci Monit 14(12):CR589–CR597PubMed Escher F, Modrow S, Sabi T, Kuhl U, Lassner D, Schultheiss HP, Noutsias M (2008) Parvovirus B19 profiles in patients presenting with acute myocarditis and chronic dilated cardiomyopathy. Med Sci Monit 14(12):CR589–CR597PubMed
57.
Zurück zum Zitat Streitz M, Noutsias M, Volkmer R, Rohde M, Brestrich G, Block A, Klippert K, Kotsch K, Ay B, Hummel M, Kühl U, Lassner D, Schultheiss HP, Volk HD, Kern F (2008) NS1 specific CD8+ T-cells with effector function and TRBV11 dominance in a patient with parvovirus B19 associated inflammatory cardiomyopathy. PLoS One 3(6):e2361CrossRefPubMedPubMedCentral Streitz M, Noutsias M, Volkmer R, Rohde M, Brestrich G, Block A, Klippert K, Kotsch K, Ay B, Hummel M, Kühl U, Lassner D, Schultheiss HP, Volk HD, Kern F (2008) NS1 specific CD8+ T-cells with effector function and TRBV11 dominance in a patient with parvovirus B19 associated inflammatory cardiomyopathy. PLoS One 3(6):e2361CrossRefPubMedPubMedCentral
58.
Zurück zum Zitat Li Y, Bourlet T, Andreoletti L, Mosnier JF, Peng T, Yang Y, Archard LC, Pozzetto B, Zhang H (2000) Enteroviral capsid protein VP1 is present in myocardial tissues from some patients with myocarditis or dilated cardiomyopathy. Circulation 101(3):231–234CrossRefPubMed Li Y, Bourlet T, Andreoletti L, Mosnier JF, Peng T, Yang Y, Archard LC, Pozzetto B, Zhang H (2000) Enteroviral capsid protein VP1 is present in myocardial tissues from some patients with myocarditis or dilated cardiomyopathy. Circulation 101(3):231–234CrossRefPubMed
59.
Zurück zum Zitat Escher F, Kühl U, Sabi T, Suckau L, Lassner D, Poller W, Schultheiss HP, Noutsias M (2008) Immunohistological detection of Parvovirus B19 capsid proteins in endomyocardial biopsies from dilated cardiomyopathy patients. Med Sci Monit 14(6):CR333–CR338PubMed Escher F, Kühl U, Sabi T, Suckau L, Lassner D, Poller W, Schultheiss HP, Noutsias M (2008) Immunohistological detection of Parvovirus B19 capsid proteins in endomyocardial biopsies from dilated cardiomyopathy patients. Med Sci Monit 14(6):CR333–CR338PubMed
Metadaten
Titel
The MOGE(S) classification for cardiomyopathies: current status and future outlook
verfasst von
Julian G. Westphal
Angelos G. Rigopoulos
Constantinos Bakogiannis
Sarah E. Ludwig
Sophie Mavrogeni
Boris Bigalke
Torsten Doenst
Matthias Pauschinger
Carsten Tschöpe
P. Christian Schulze
Michel Noutsias
Publikationsdatum
19.07.2017
Verlag
Springer US
Erschienen in
Heart Failure Reviews / Ausgabe 6/2017
Print ISSN: 1382-4147
Elektronische ISSN: 1573-7322
DOI
https://doi.org/10.1007/s10741-017-9641-4

Weitere Artikel der Ausgabe 6/2017

Heart Failure Reviews 6/2017 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.